Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.18 EUR
Change Today -0.116 / -3.52%
Volume 0.0
LT3 On Other Exchanges
As of 1:35 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

axogen inc (LT3) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/8/15 - €3.53
52 Week Low
08/15/14 - €1.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AXOGEN INC (LT3)

Related News

No related news articles were found.

axogen inc (LT3) Related Businessweek News

No Related Businessweek News Found

axogen inc (LT3) Details

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, a proprietary processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. It also offers AxoTouch Two Point Discriminator, a measurement tool for determining innervation density and sensory function. The company’s products are used by plastic reconstructive surgeons, and orthopedic and plastic surgeons during surgical interventions to repair various nerve injuries. It markets its products in the United States, the United Kingdom, Singapore, Israel, Canada, Switzerland, Austria, and Spain. AxoGen, Inc. is headquartered in Alachua, Florida.

84 Employees
Last Reported Date: 03/5/15

axogen inc (LT3) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $314.5K
Senior Vice President of Business Development...
Total Annual Compensation: $251.6K
Senior Vice President of Sales
Total Annual Compensation: $314.6K
Chief Marketing Officer
Total Annual Compensation: $231.1K
Compensation as of Fiscal Year 2013.

axogen inc (LT3) Key Developments

AxoGen, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 04:30 PM

AxoGen, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 04:30 PM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States.

AxoGen, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for 2015

AxoGen, Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, revenues totaled $4.79 million, a 61% increase compared to $2.98 million in the prior year fourth quarter. Net loss was $6.5 million or $0.35 per share compared to net loss of $4.1 million or $0.24 per share for the fourth quarter of 2013. For the year, revenues were $16,817,403 against $10,947,361 a year ago. Loss from operations was $9,800,790 against $9,592,205 a year ago. Net Loss available to common shareholders was $17,710,476 against $14,556,885 a year ago. Basic and diluted loss per share was $0.99 against $1.08 a year ago. Net cash used for operating activities was $10,451,059 against $10,444,758 a year ago. Purchase of property and equipment was $542,045 against $178,776 a year ago. Acquisition of intangible assets was $52,002 against $65,189 a year ago. Based on the market's increasing awareness of the company's product portfolio, continued expansion of its sales footprint and current sales pipeline, the company currently anticipates 2015 full year revenue to exceed $24 million and annual gross margin in the mid to high 70% range.

AxoGen, Inc. to Report Q4, 2014 Results on Mar 05, 2015

AxoGen, Inc. announced that they will report Q4, 2014 results After-Market on Mar 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LT3:GR €3.18 EUR -0.116

LT3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.91 USD -0.24
Integra LifeSciences Holdings Corp $59.87 USD -1.26
Stryker Corp $92.50 USD +0.32
View Industry Companies

Industry Analysis


Industry Average

Valuation LT3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AXOGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at